Stay updated on Pembrolizumab for Cancer of Unknown Primary Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for Cancer of Unknown Primary Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for Cancer of Unknown Primary Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant piece of information regarding the modernization of ClinicalTrials.gov data ingest in July 2025 has been deleted.
    Difference
    0.9%
    Check dated 2025-07-04T13:00:13.000Z thumbnail image
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.7%
    Check dated 2025-06-20T02:56:56.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.3.
    Difference
    0.1%
    Check dated 2025-06-13T00:33:42.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    The web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.
    Difference
    1%
    Check dated 2025-05-29T15:17:09.000Z thumbnail image
  6. Check
    71 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-05-01T03:33:03.000Z thumbnail image
  7. Check
    85 days ago
    Change Detected
    Summary
    The webpage has been updated to include the study's collaborators, Merck Sharp & Dohme LLC, and the study chair, Harpreet Wasan, MBBS, FRCP, from Imperial College London. Additionally, the revision number has been updated from v2.14.3 to v2.15.0.
    Difference
    53%
    Check dated 2025-04-16T14:25:13.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for Cancer of Unknown Primary Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Cancer of Unknown Primary Clinical Trial page.